We are excited to announce that?registration?for the 2025 edition of the?Fragment-Based Lead Discovery Conference?is now open!?Do you want to participate more actively? Then submit your abstract and get a chance to speak with Prof Anna K. H. Hirsch from Universit?t des Saarlandes and Prof Steve Fesik from Vanderbilt University: https://lnkd.in/guvzCjWj
关于我们
After a significant hiatus, we are excited to once again host FBLD 2024 in the heart of Boston at the George Sherman Union, part of the BU Campus from September 22nd through 25th 2024. We are delighted to host the first in-person event after a six-year break. Fragment-Based Lead Discovery continues to be a rapidly growing, multidisciplinary endeavour. As such delegates with expertise in chemistry, biochemistry and related disciplines will be at the conference, providing you with excellent access to your key customers. We look forward to welcoming both delegates and exhibitors to engage in a high-quality meeting with talks, workshops, poster sessions and vendor exhibits exploring all aspects of fragment-based drug discovery.
- 网站
-
fbldconference.org
FBLD Conference的外部链接
- 所属行业
- 教育业
- 规模
- 2-10 人
- 总部
- Boston，MA
- 类型
- 非营利机构
地点
-
主要
获取路线
US，MA，Boston
动态
-
FBLD is returning to Europe! We are excited to host FBLD 2025 at the historical?Fitzwilliam College, University of Cambridge in Cambridge, UK from 21 to 24 September 2025. The event is co-hosted by Monash Institute of Pharmaceutical Sciences and Astex Pharmaceuticals Visit fbldconference.org. for more details.
-
-
The final countdown! Only 4 days until FBLD 2024 in Boston. We are looking forward to fascinating talks, fruitful discussions and meeting new colleagues. Want to come but haven't registered yet? There's still some time left: https://lnkd.in/gPTWxS9Z
?? There are only two weeks left until FBLD 2024! ?? Secure your spot now:?https://lnkd.in/gPTWxS9Z Get the chance to find out the latest trends in FBDD and broaden your network within this wonderful community. Attached is the program of the conference. A detailed conference booklet will follow soon.
-
?? There are only two weeks left until FBLD 2024! ?? Secure your spot now:?https://lnkd.in/gPTWxS9Z Get the chance to find out the latest trends in FBDD and broaden your network within this wonderful community. Attached is the program of the conference. A detailed conference booklet will follow soon.
-
We are delighted to announce that we are offering a FREE workshop on?Sunday, 22 September?together with every FBLD?registration. Register now to get access to this famous workshop with Daniel Erlanson and Ben Davis: https://bit.ly/4cG9lFD Already registered but still keen to join? Just?contact us?via [email protected] and we will add you to the list. But hurry up, spaces are limited.
-
-
It's less than a month to FBLD 2024 and we couldn't be more excited. Registration closes in 2 weeks so make sure to secure your ticket: https://bit.ly/4cG9lFD We put together an?exciting program?with the latest on FBLD methods, crystallography, multi-component targets and DNA-encoded fragments - to just capture a few examples: https://lnkd.in/es5Trr9a Register?now and join us in Boston!?
-
Really honored to be a part of this illustrious group!
We are pleased to welcome Dr. Daniel Erlanson to the Drug Hunter Scientific Advisory Board! ? Dr. Erlanson brings over 25 years of experience in the biotech industry. Currently, he is Chief Innovation Officer of Frontier Medicines. Before that he co-founded and led chemistry at Carmot Therapeutics, Inc. Therapeutics, which collaborated with Amgen on the discovery of the first FDA-approved KRASG12C inhibitor, sotorasib. Carmot also put three of its own internally discovered drugs into the clinic before being acquired by Roche in early 2024.? ? Daniel is a widely recognized thought leader in fragment-based drug discovery (FBDD), serving as the editor of the popular Practical Fragments blog (https://lnkd.in/dStCAyZW), co-editor of two books on FBDD, and the inventor or author on over 70 granted US patents and peer-reviewed publications. ? Daniel started his industry career at Sunesis Pharmaceuticals, Inc., where he co-invented the covalent disulfide tethering approach for finding fragments and advancing them to leads, enabling the discovery of drugs for targets once thought to be intractable for small molecules, such as KRAS. Daniel received his BA in chemistry from Carleton College, his PhD from Harvard University in the laboratory of Greg Verdine, and did postdoctoral work in Jim Wells’ group at Genentech. ? We are privileged to have Daniel Erlanson on our Scientific Advisory Board, whose scientific leadership enhances Drug Hunter in our mission to empower the world’s scientists to make tomorrow’s medicines. ? Welcome Daniel!
-
-
??The Early Bird Discount for FBLD 2024 ends today. ??Make sure to register via https://lnkd.in/gPTWxS9Z to benefit from great deals.
-
-
?? Early Bird closing soon! ?? Only 4 days until the early bird discount closes. Make sure to register before midnight EDT on 12 August to save $$ on your registration for FBLD 2024! https://lnkd.in/gPTWxS9Z
-